Cantor Fitzgerald Analysts Reiterate a “Buy” Rating on Salix Pharmaceuticals (SLXP)
Salix Pharmaceuticals (NASDAQ: SLXP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday.
Separately, analysts at Jefferies raised their price target on shares of Salix Pharmaceuticals to $50.00 in a research note to investors on Tuesday. Analysts at UBS AG (NYSE: UBS) reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note to investors on Friday, December 2nd. Also, analysts at UBS AG (NYSE: UBS) raised their price target on shares of Salix Pharmaceuticals to $47.00 in a research note to investors on Friday, December 2nd.
Shares of Salix Pharmaceuticals traded up 6.38% during mid-day trading on Tuesday, hitting $45.99. Salix Pharmaceuticals has a 52 week low of $25.64 and a 52 week high of $49.05. The stock’s 50-day moving average is $38.78 and its 200-day moving average is $34.95. The company has a market cap of $2.720 billion and a price-to-earnings ratio of 33.25.
Jefferies Analysts Reiterate a “Hold” Rating on Watson Pharmaceuticals Incorporated (WPI)
Watson Pharmaceuticals Incorporated (NYSE: WPI)‘s stock had its “hold” rating reaffirmed by equities research analysts at Jefferies in a research note issued to investors on Tuesday. The analysts currently have a $70.00 price target on the stock.
Separately, analysts at Citigroup (NYSE: C) reiterated a “buy” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday. They now have a $82.00 price target on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday. Also, analysts at Needham & Company reiterated a “hold” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday.
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates manufacturing, distribution, research and development (R&D), and administrative facilities in the United States of America. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2009, the Company marketed approximately 170 generic pharmaceutical product families and 30 brand pharmaceutical product families and distributed approximately 8,000 stock-keeping units (SKUs) through its Distribution business in the United States. On December 2, 2009, Watson completed the acquisition of Robin Hood Holdings Limited and Cobalt Laboratories, Inc. On November 26, 2009, the Company acquired Arrow Group. Watson also acquired a 36% ownership interest in Eden Biopharm Group (Eden).
Shares of Watson Pharmaceuticals Incorporated traded up 1.93% during mid-day trading on Tuesday, hitting $60.80. Watson Pharmaceuticals Incorporated has a 52 week low of $50.47 and a 52 week high of $73.35. The stock’s 50-day moving average is $63.97 and its 200-day moving average is $66.1. The company has a market cap of $7.731 billion and a price-to-earnings ratio of 41.02.
AAIPharma Services Appoints Vice President of Packaging Services
AAIPharma Services Corp., a leading provider of pharmaceutical product development services, announced today that it has appointed Kevin Flanagan to vice president of packaging services, where he will oversee the company’s Packaging and Distribution functions at the Wilmington headquarters. Flanagan joins the firm from Compass Pharma Services, a ventured-backed pharmaceutical contract packaging firm, where he served as president.
“I am delighted to have an executive of Kevin Flanagan’s caliber join the AAIPharma team,” said Patrick Walsh, Chief Executive Officer of AAIPharma. “Kevin’s deep knowledge of the packaging industry, particularly in the design and distribution of pharmaceutical products, will be a huge asset to AAIPharma as we expand and enhance our business offerings.”
Flanagan brings more than 30 years of experience in the pharmaceutical packaging components and contract packaging services industries. He founded National Packaging Systems, a manufacturing company that specialized in the design, packaging and distribution of clinical trial supplies, in 1998. National Packaging Systems was acquired by Corning, Inc., where Flanagan became part of the group from Corning Pharmaceutical Services that formed Covance. Flanagan also held leadership roles at PA Early Stage Partners and Research Trials LLC.
Flanagan received his bachelor of arts from Villanova University. He is a recipient of both the Ben Franklin Technology Center Innovation Award for Entrepreneurial Achievement and the Greater Philadelphia Venture Group Entrepreneur of the Year Award.